FMC Corporation Files First Global Regulatory Submission for Rimisoxafen with United States Environmental Protection Agency

Rhea-AI Summary

FMC (NYSE:FMC) has filed the first global regulatory submission for its new herbicide active ingredient rimisoxafen with the U.S. EPA. The dossier seeks approval for use on corn, soybean, sunflower and select pulse crops.

Rimisoxafen, discovered at FMC's Stine Research Center, is the first herbicide ever classified by HRAC as a dual mode of action active (Groups 12 and 32), inhibiting two weed biochemical pathways to help delay resistance. Extensive testing shows activity against troublesome weeds Palmer amaranth and waterhemp. This is FMC's third novel herbicide advanced to regulatory submission in recent years. Rimisoxafen is not yet registered or permitted for sale or use in any country.

Positive

• First global regulatory submission for rimisoxafen filed with U.S. EPA
• Dual mode of action herbicide classified in HRAC Groups 12 and 32
• Extensive testing shows activity against Palmer amaranth and waterhemp
• Third novel herbicide active advanced to submission in recent years
• Targets U.S. corn and soybean market of 70M+ hectares and $6B weed control spend

Negative

• Rimisoxafen not registered for sale or use in any country
• Commercialization timing and outcomes depend on regulatory review and approvals

News Market Reaction – FMC

-0.46%

7 alerts

-0.46% Session close to close

$1.43B Market Cap

0.2x Rel. Volume

In the Jul 9 session, FMC declined 0.46%, reflecting a mild negative market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Submitting rimisoxafen’s first regulatory dossier to the EPA, with a dual mode of action and exposur...

Analysis

Submitting rimisoxafen’s first regulatory dossier to the EPA, with a dual mode of action and exposure to a U.S. weed control market above $6 billion, highlights R&D strength, though commercialization depends on future approvals and competitive resistance management.

Key Figures

Research duration: over a decade Field and greenhouse studies: more than 1,000 studies HRAC groups: Groups 12 and 32 +5 more

8 metrics

Research duration over a decade biology research behind rimisoxafen

Field and greenhouse studies more than 1,000 studies development program for rimisoxafen

HRAC groups Groups 12 and 32 dual mode of action classification for rimisoxafen

Biochemical pathways inhibited two pathways mechanism of action in weeds

Corn and soybean area more than 70 million hectares U.S. area grown annually

Weed control spend more than $6 billion annually U.S. growers’ weed control market

Weed survey year 2025 Weed Science Society of America National Weed Survey

Novel herbicide ingredients third active ingredient number of novel herbicides FMC has advanced recently

Historical Context

5 past events · Latest: Jun 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 30	strategic equity investment	Positive	-4.8%	Tessenderlo’s $400M minority stake to support roughly $1B targeted debt reduction.
Jun 23	sale‑leaseback transaction	Positive	-0.1%	Agreement to sell Newark property for about $114M with leaseback to fund debt cuts.
Jun 22	earnings date announcement	Neutral	-0.1%	Scheduling of second quarter 2026 earnings release and webcast conference call.
Jun 16	rimisoxafen license deal	Positive	+3.3%	Co‑exclusive supply and license pact with Corteva plus $200M prepurchase payment.
Jun 10	investor conference appearance	Neutral	+4.3%	CEO and CFO participation in Wolfe Research conference with live investor webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent FMC headlines have produced mixed single‑day reactions, with both positive and negative moves around strategic and partnership news.

Key Terms

dual mode of action, herbicide-resistant, regulatory dossier, broadleaf weeds

4 terms

dual mode of action technical

"advance this breakthrough dual mode of action technology through the regulatory process"

Dual mode of action describes a medical product that works through two different biological or physical processes to produce its effect — for example one component may directly target disease-causing agents while the other reduces symptoms or protects tissue. Investors care because two complementary ways of working can make a product more effective, broaden its uses and raise barriers to competitors, but they can also increase development complexity, regulatory scrutiny and costs.

herbicide-resistant technical

"Herbicide-resistant weeds continue to challenge growers and drive demand"

Herbicide-resistant describes plants that survive otherwise effective weed-killing chemicals, either because they were bred or engineered to tolerate those chemicals (common in some crops) or because wild weeds have evolved resistance. For investors, it matters because resistance changes farm costs, yields and product demand—driving spending on different chemicals, seeds or farm practices, influencing agricultural company revenues and regulatory or market risks.

regulatory dossier regulatory

"announced it has submitted the regulatory dossier for rimisoxafen to the United States"

A regulatory dossier is a comprehensive package of documents a company prepares to show regulators that a product — commonly a drug, vaccine, or medical device — meets legal, safety and effectiveness standards. For investors it matters because regulators use the dossier to decide approvals, labeling, and market access; its completeness and quality influence the timing and likelihood of permission to sell, much like a complete building permit application affects whether and when construction can start.

broadleaf weeds technical

"Palmer amaranth and waterhemp rank as the most troublesome broadleaf weeds in U.S. soybean production"

Broadleaf weeds are unwanted plants with wide, flat leaves (think dandelions or plantain) rather than narrow, grass-like blades. For investors, they matter because these weeds compete with crops and lawns for sunlight, water and nutrients, affecting yields and maintenance costs; they also drive demand, sales and regulatory scrutiny for herbicides, seed treatments and weed-control technologies, much like pests shape the market for pest-control products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The submission marks an important milestone in FMC's efforts to advance next-generation weed control technologies as resistance pressure intensifies in key row crop markets.

PHILADELPHIA, July 8, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has submitted the regulatory dossier for rimisoxafen to the United States (U.S.) Environmental Protection Agency (EPA), the first regulatory submission globally for this groundbreaking herbicide active ingredient. The U.S. submission covers use on corn, soybean, sunflower and select pulse crops.

"Filing the first regulatory dossier for rimisoxafen with the EPA represents a significant milestone for FMC," said Seva Rostovtsev, executive vice president and chief technology officer at FMC. "Years of innovation and scientific discovery have brought us to this point, and we are proud to advance this breakthrough dual mode of action technology through the regulatory process on behalf of growers facing increasingly complex weed resistance challenges."

Discovered at FMC's Stine Research Center and built on over a decade of biology research and more than 1,000 field and greenhouse studies, rimisoxafen is the first herbicide active ingredient ever classified as a dual mode of action by the Global Herbicide Resistance Action Committee (HRAC). Designated under Groups 12 and 32, rimisoxafen inhibits two distinct biochemical pathways in weeds, which helps delay resistance development compared to single mode of action herbicides.

Herbicide-resistant weeds continue to challenge growers and drive demand for new and underutilized modes of action. According to a 2025 Weed Science Society of America National Weed Survey, Palmer amaranth and waterhemp rank as the most troublesome broadleaf weeds in U.S. soybean production¹. In extensive field testing, rimisoxafen has demonstrated consistent activity against both. The U.S. represents a critical market for next-generation weed control solutions with more than 70 million hectares of corn and soybeans grown annually and growers spending more than $6 billion annually on weed control.

Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in recent years, following Isoflex™ active and Dodhylex™ active. Together, these submissions reflect the depth and productivity of FMC's R&D pipeline and the company's commitment to advancing next-generation crop protection solutions through the regulatory process.

FMC intends to pursue regulatory submissions for rimisoxafen in additional key geographies and crop segments as part of its global development program. Timing and outcomes are subject to regulatory review and approval in each jurisdiction. Rimisoxafen is not currently registered for sale or use in the United States or any other country. No offer for sale, sale or use of this product is permitted prior to receipt of all required regulatory approvals.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn^®.

Dodhylex and Isoflex are trademarks of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

¹ Van Wychen, L. (2025). 2025 Survey of the Most Common and Troublesome Weeds in Broadleaf Crops, Fruits & Vegetables, and Hemp in the United States and Canada. Weed Science Society of America National Weed Survey Dataset. Available at: https://wssa.net/2025/11/wssa-survey-shows-an-urgent-need-for-new-weed-control-strategies/

View original content to download multimedia:https://www.prnewswire.com/news-releases/fmc-corporation-files-first-global-regulatory-submission-for-rimisoxafen-with-united-states-environmental-protection-agency-302821131.html

SOURCE FMC Corporation

FAQ

What did FMC (FMC) announce about rimisoxafen and the U.S. EPA on July 8, 2026?

FMC announced it filed the first global regulatory submission for its herbicide active ingredient rimisoxafen with the U.S. Environmental Protection Agency. According to FMC, the dossier seeks approval for use on corn, soybean, sunflower and select pulse crops in the United States.

What is rimisoxafen and why is it important for FMC (FMC) investors?

Rimisoxafen is a new herbicide active ingredient with a dual mode of action targeting two weed biochemical pathways. According to FMC, it is the first herbicide classified by HRAC in both Groups 12 and 32, supporting resistance management in major row crops.

How does rimisoxafen address herbicide-resistant weeds in U.S. row crops for FMC (FMC)?

Rimisoxafen is designed to control key herbicide-resistant weeds such as Palmer amaranth and waterhemp in soybeans. According to FMC, extensive field testing has shown consistent activity, targeting a U.S. corn and soybean area exceeding 70 million hectares.

Is rimisoxafen from FMC (FMC) already approved or available for farmers to use?

Rimisoxafen is not currently registered for sale or use in the United States or any other country. According to FMC, no offer for sale, sale or use is allowed until all required regulatory approvals are obtained in each jurisdiction.

What market opportunity could rimisoxafen create for FMC (FMC) if approved?

If approved, rimisoxafen would target the large U.S. corn and soybean weed control market. According to FMC, more than 70 million hectares are grown annually, with growers spending over $6 billion each year on weed control solutions.

How does rimisoxafen fit into FMC (FMC) R&D pipeline strategy?

Rimisoxafen is the third novel herbicide active FMC has advanced to regulatory submission in recent years. According to FMC, it follows Isoflex active and Dodhylex active, signaling a productive R&D pipeline in next-generation crop protection solutions.